检索结果-南通市图书馆

Patient-centric dose equivalency pilot study of incobotulinumtoxin a(xeomin)*** a(dysport)in the treatment of glabellar frown lines

引用

Plastic and Aesthetic Research 2015年第1期2卷 12-16页

作者： Jonathan Bank Nicole A.Phillips Laurie A.Casas Department of Surgery Section of Plastic and Reconstructive SurgeryUniversity of Chicago Medical CenterChicagoIL 60026USA Department of Surgery Division of Plastic SurgeryBrigham and Women’s HospitalBostonMA 02115USA

Aim:Incobotulinumtoxin A(xeomin)has been proposed as an alternative to abobotulinumtoxin A(dysport)and onabotulinumtoxin A(Botox)in the treatment of glabellar frown lines.A recent study is comparing abobotulinumtoxin A and onabotulinumtoxin A revealed equivalent efficacy with a dose conversion ratio of 2.5:*** sought to establish effectiveness and dosing equivalency of incobotulinumtoxin A *** ***:Inclusion criteria for this pilot study included patients of a single surgeon(LAC)who had previously received a constant dose of abobotulinumtoxin A over at least four consecutive treatment sessions for the previous 12 months to achieve an 85-90%elimination of dynamic glabellar frown *** primary outcome sought dose comparison between established maintenance abobotulinumtoxin A dosing and incobotulinumtoxin A first-time dosing.A 2:1 conversion(abobotulinumtoxin A:incobotulinumtoxin A)was chosen in most *** outcomes were patient-reported onset of effect,physician-assessed effect at 10-12 weeks,pain associated with administration,and patient perceived need for re-treatment at 2 ***:A total of 32 subjects were *** mean dose of incobotulinumtoxin A was 17.1 units(±6.1,the median dose 20 units).The mean dose of abobotulinumtoxin A was 27.6(±11.7,the median dose 27.5 units).The mean difference in treatment units was 10.5(95%confidence interval,P<0.001).Among 30 patients who reported effect onset,the median was 8.5 days,with a range of *** 10-12 weeks,muscle paralysis was assessed to be 69.2%(±27.3),vs.90.3%(±1.8)with abobotulinumtoxin A(P<0.001).The majority of patients rated pain of administration as equal or greater to that of abobotulinumtoxin A(63%and 22%,respectively).Three patients(9%)required re-treatment at 2 weeks with abobotulinumtoxin A due to lack of effective treatment with incobotulinumtoxin *** A re-treatment was chosen by the ***:We found incobotulinumtoxin A at 17.1

关键词： Abobotulinumtoxin A glabellar frown lines incobotulinumtoxin A rhytids

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：